Baring

Baring buys Japan’s Bushu Pharma for $670m

The fund agreed to buy the contract drug maker from Tokio Marine Capital, the largest private equity deal in Japan’s healthcare sector this year.

Baring Private Equity Asia said it has agreed to acquire Bushu Pharmaceuticals from Tokio Marine Capital at an enterprise value of Y77.3 billion $670 million.

Saitama-headquartered Bushu, which makes drugs for third parties on a contract basis, expanded its capacity to 10 billion tablet dosages per year by buying a plant in Misato in March from Japanese drug company Eisai, which was cutting costs.

Japan’s Pharmaceutical Affairs Law changed in 2005 to allow Japanese license holders to outsource 100% of drug manufacturing. This business, called contract manufacturing, is still a small percentage of overall drug manufacturing in Japan at 8% compared with 18% globally.

...
¬ Haymarket Media Limited. All rights reserved.

FinanceAsia has updated its subscription model.

Registered readers now have the opportunity to read 5 articles from our award-winning website for free.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences.

To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222

Article limit is reached.

Hello! You have used up all of your free articles on FinanceAsia.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences. To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222